Physician profile
Megan Ash
NPI 1336678234
$3,963.99
in general payments reported to CMS, 2019-2025
37 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $630 · 2023: $931 · 2024: $1,185 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,333.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $907.80 | 2022-2025 | Vraylar, Ubrelvy, Linzess |
| Novo Nordisk INC | $570.06 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $290.03 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $283.56 | 2024-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $203.73 | 2022-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $149.24 | 2022-2025 | Bexsero, Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $147.03 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.92 | 2022-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $128.68 | 2023-2025 | Rexulti |
| Pfizer INC. | $111.87 | 2023-2025 | |
| Axsome Therapeutics, INC. | $82.00 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $77.07 | 2022-2023 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $76.37 | 2022-2025 | Caplyta |
| Lundbeck LLC | $74.53 | 2025 | Rexulti |
| Exact Sciences Corporation | $72.57 | 2024-2025 | Cologuard Collection Kit |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $58.26 | 2024 | |
| Jazz Pharmaceuticals INC. | $54.14 | 2022-2024 | |
| Medtronic, INC. | $49.26 | 2023-2024 | Intellis Adaptivestim |
| Ucb, INC. | $43.40 | 2025 | Bimzelx |
| Amarin Pharma, INC. | $42.89 | 2022 | |
| Alnylam Pharmaceuticals INC. | $38.40 | 2023-2024 | Onpattro |
| Corium, LLC | $37.79 | 2022-2025 | Azstarys |
| Abbott Laboratories | $35.60 | 2024-2025 | Freestyle Libre 3 |
| Biogen, INC. | $35.10 | 2025 | Zurzuvae |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.57 | 2022-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $29.78 | 2022-2023 | Eliquis |
| Vanda Pharmaceuticals INC. | $28.35 | 2022 | |
| Phathom Pharmaceuticals, INC. | $28.19 | 2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $24.68 | 2022 | |
| Sumitomo Pharma America, INC. | $21.22 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $16.55 | 2023 | Verquvo, Steglatro, Belsomra |
| Axonics, INC. | $14.94 | 2022 | |
| Amgen INC. | $14.50 | 2023 | Otezla, Repatha |
| Boston Scientific Corporation | $13.53 | 2025 | Wavewriter Alpha Prime 16 |
| Sanofi-Aventis U.S. LLC | $13.30 | 2022 | |
| Echosens North America, INC. | $13.04 | 2025 | Fibroscan |
| Kowa Pharmaceuticals America, INC. | $12.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Ash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.